Results 191 to 200 of about 119,169 (307)

Immune Checkpoint Inhibitors in Malignant Melanoma: Anti-PD-1, Anti-CTLA-4 and Anti-LAG-3 Therapies. [PDF]

Curr Oncol Rep
Allen-Tejerina AM, Giannakis P, Ho Lai Yau T, Hillyar CRT, Rallis KS.   +4 more
europepmc   +1 more source

Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T‐Cell Enhancement in Immunocompetent HLA‐Transgenic Mice

Allergy, EarlyView.
Upregulated HLA‐B*57:01 expression in Tg/KO mice amplifies abacavir‐specific CD8+ T‐cell activation, driven by enhanced antigen presentation. Abacavir treatment induces robust pDC expansion and IFN‐α production, which selectively suppresses memory Treg populations.
SuJin Hwang, Telly Sepahpour, Stephanie Kortchak, Kirthiram Krishnaveni Sivakumar, Spyros Karaiskos, Ngoc Pham, Yura Jang, Montserrat Puig, Michael Norcross   +8 more
wiley   +1 more source

CTLA-4 blockade shifts the B cell repertoire toward autoimmunity. [PDF]

J Clin Invest
Çakan E, Wang M, Dai Y, Mirouse A, Villanueva-Pachas CR, Bouis D, Boeckers JM, Gera R, Yraita S, Clapp L, Perdigoto AL, Delmotte FR, Massad C, Bacchiocchi A, Ring AM, Kluger Y, Kluger HM, Herold KC, Meffre E.   +18 more
europepmc   +1 more source

TNF Pathway‐Mediated Tolerogenic T‐Cell Trajectory Driven by Allergen Immunotherapy

Allergy, EarlyView.
The study shows that AIT re‐establishes local immune equilibrium by restoring Th17/Treg balance, while circulating Th17 cells remain functionally impaired. The transition from pro‐inflammatory Th17 to regulatory T cell states during AIT identifies Tr17 cells as an intermediate cell population.
Helen S. Charles, Amr A. Gabr, Shu‐Hung Wang, Ulrich M. Zissler, Sonja Heine, Alexander Heldner, Sebastian Kotz, Lisa Pechtold, Lynn S. zur Bonsen, Dimitrii Pogorelov, Josephine Kau, Mirjam Plaschke, Miriam Hills, Ferdinand Guerth, Madlen Oelsner, Caspar Ohnmacht, Francesca Alessandrini, Simon Blank, Adam M. Chaker, Carsten B. Schmidt‐Weber, Constanze A. Jakwerth   +20 more
wiley   +1 more source

Investigation of the CTLA-4-CD28 Axis in Oral Squamous Cell Carcinoma. [PDF]

J Clin Med
Feldmeier F, Weber M, Pacelli F, Vogl C, Glajzer J, Trumet L, Buchbender M, Geppert C, Kesting M, Ries J.   +9 more
europepmc   +1 more source

What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta‐analysis of ocular immune‐related adverse events

Acta Ophthalmologica, EarlyView.
Abstract Purpose Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune‐related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI‐associated DED and to evaluate factors contributing to variability across studies.
Kai‐Yang Chen, Hoi‐Chun Chan, Chi‐Ming Chan   +2 more
wiley   +1 more source

Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) tumour expression in gastric carcinoma. [PDF]

Indian J Med Res
Kottarathil MS, D'Cruze L, Dhanabal D, K H.   +3 more
europepmc   +1 more source

Infection control in the brain and the eye

Acta Ophthalmologica, EarlyView.
Abstract The Central Nervous System (CNS), comprising the brain and the eye, is considered to have a ‘privileged’ mechanism for dealing with immunological challenge (immune privilege, IP). CNS IP has been revealed through experiments using foreign protein antigens and cell and tissue alloantigens (grafts), but evidence for a role for IP in modulating ...
John V. Forrester, Paul G. McMenamin, Samantha J. Dando   +2 more
wiley   +1 more source

Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies. [PDF]

Front Immunol
Wang X, He J, Ding G, Tang Y, Wang Q.
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source